Investors and others in the field of Parkinson's disease (PD) are weighing the odds of two major players in treating "off" episodes: Sunovion Pharmaceuticals Inc. with apomorphine sublingual film (APL-130277), for which the FDA set Tuesday as the PDUFA date; and Acorda Therapeutics Inc., of Ardsley, N.Y., preparing to launch Inbrija (levodopa inhalation powder) this quarter. Off periods are times when PD symptoms return because of low dopamine levels between doses of oral carbidopa/levodopa.